Depomed
Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…
April 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market
Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …
Depomed criticised by investors and urged to explore potential sale
April 11, 2016Sales and Marketing Depomed, board, horizon, sale, starboard, starboard value
Only a few short months after fighting off a $1 billion bid from Horizon Pharma, investors at Depomed have called …
Horizon Pharma receives third rejection from Depomed
August 21, 2015Sales and Marketing Depomed, Horizon Pharma, pharma mergers and acquisitions
Depomed has announced that its board has unanimously rejected Horizon Pharma’s third proposal to buy the California-based company. Following its …
Takeover hostilities resume between Depomed and Horizon
August 10, 2015Sales and Marketing Depomed, horizon, hostile bid, nucynta, takeover, tapentadol
The bitter takeover row between Horizon and Depomed has escalated after Depomed dismissed its suitor’s latest advances, and warned it …
Depomed rejects Horizon’s latest takeover bid
July 30, 2015Sales and Marketing Depomed, horizon, mergers and acquisitions, takeovers
Depomed has rejected Horizon Pharma’s latest bid, stating the proposal is ‘inadequate’ and ’undervalues’ the company. The Irish pharma company …
Horizon attempts a hostile $3bn Depomed takeover
July 9, 2015Manufacturing and Production, Research and Development, Sales and Marketing Depomed, M&A, MA, acquisitions, horizon, mergers, takeover
Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion. Horizon, a biopharma company focussed …
Depomed hires Kyalin chief executive
July 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Depomed, Srinivas Rao
California-based speciality pharma firm Depomed has appointed Dr Srinivas Rao as its chief medical officer (CMO) and senior VP. Rao …
Depomed pulls diabetes drug Glumetza
June 21, 2010Manufacturing and Production Depomed, Glumetza, manufacturing compliance
Another pharmaceutical manufacturer has been forced to recall products because of contamination caused by a chemical used to treat wooden …
